Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma (pages 3599–3606)
Pierre Giglio, Megha Dhamne, Kenneth R. Hess, Mark R. Gilbert, Morris D. Groves, Victor A. Levin, Sanghee L. Kang, Sandra E. Ictech, Vivien Liu, Howard Colman, Charles A. Conrad, Monica Loghin, John de Groot, W. K. Alfred Yung and Vinay K. Puduvalli
Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26663
In this phase 2 trial that combined the cytotoxic agent irinotecan with the antiangiogenic agent thalidomide, with the hypothesis that this would target 2 critical biological processes of World Health Organization grade III anaplastic gliomas, a subset of patients experienced prolonged progression-free and overall survival; however, the study did not meet its statistical endpoint of progression-free survival at 6 months. A trial of the more potent thalidomide analogue, lenalidomide, with irinotecan is currently ongoing.